AstraZeneca will “redeploy resources” through a new restructuring program. Meanwhile, Alnylam shares sold off on fears ...
The parent of cell therapy maker Gamida Cell will be the lead bidder in a court-supervised auction of Karyopharm, which ...
Lilly’s better-than-expected results allayed concerns — for now — over GLP-1 pricing pressure. Elsewhere, Novartis withstood ...
The drugmaker’s market value swelled by more than $7 billion on findings suggesting a recently-acquired medicine could become ...
RFK Jr. has given notice that the agency won’t take enforcement action on six peptides that controversially won a contested ...
The buyout hands Ferring rights to a technology capable of simplifying the lengthy and burdensome process of in vitro ...
The highest dose of retatrutide beat Ozempic on measures of blood sugar and weight loss, but was also associated with higher ...
The plan builds on recent FDA moves to speed "personalized" treatments by offering an approval framework for therapies ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results